REG - Niox Group PLC - AGM Statement

NioxAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU1527Fa&default-theme=true

RNS Number : 1527F  Niox Group PLC  21 May 2026

NIOX Group plc

("NIOX" or the "Company" and, together with its subsidiaries, the "Group")

 

AGM Statement

( )

Oxford, UK - 21 May 2026: NIOX Group plc (AIM: NIOX),  a medical device
company focused on point-of-care FeNO testing for the diagnosis, monitoring
and management of asthma and COPD, is holding its Annual General Meeting at
11.00 am today at the Magdalen Centre, 1 Robert Robinson Ave, The Oxford
Science Park, Oxford, OX4 4GA.

 

Trading Update

 

We are pleased to report that trading for the year to date has been in line
with management expectations, with cash of £22.3 million as at 30 April 2026
following payment of prior-year bonuses (31 December 2025: £19.9 million). A
trading update for the six months ending 30 June 2026 will be released in
mid-July.

 

NIOX has signed a ten-year exclusive supply agreement with its FeNO sensor
supplier. This allows NIOX to make targeted investments in the sensor supplier
to increase manufacturing capacity, strengthen long-term supply security and
enhance operational resilience as the business continues to scale globally.

 

NIOX remains focused on its core strategic priorities for 2026, which are:

·      Increasing the penetration of FeNO testing and the use of NIOX®
in the US.

·      Rolling out the NIOX PRO® device, with regulatory approvals
expected across various markets throughout 2026.

·      Continuing the development of the NIOX MyNO® home-use device.

 

 

-Ends-

 

 For further information, please contact:

 NIOX Group plc                                         +44 (0) 3303 309 356

 Jonathan Emms, Chief Executive Officer

 Sarah Duncan, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)  +44 (0) 20 7496 3000

 Jen Boorer / James Fischer

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMPPUWCAUPQGAU



            Copyright 2019 Regulatory News Service, all rights reserved